Blog posts
Ahead of ASCO: Opportunities for A More Modern, Equitable Oncology Enterprise
In the lead-up to ASCO 2024 the oncology enterprise has much to celebrate. New drug approvals at FDA reached a three-decade high with anticancer drugs representing the largest percentage of new approvals. EHR vendors are making proactive commitments to cancer data standards to support scientific breakthroughs and more effective cancer treatment. And, for the first time ever, payers are offering a new reimbursable pathway for improved cancer outcomes via comprehensive supportive care.
Patient perspectives: A year of pharma webinars showcase what’s working and what needs work
Learn what industry topics, trends, and focuses are being well received by patients and caregivers with this blog.
J.P. Morgan Week 2023: Trends, highlights, and themes from this year’s conference
See what key trends and takeaways were at the 2023 JPM conference and how they'll drive the landscape of pharma.
2023: The year of the site. We are listening.
As 2022 rounds the bend, the life science industry is at a critical juncture in the adoption of the decentralized clinical trial (DCT) model.
How we standardized deploying vaccine studies in five weeks
By Musaddiq Khan, VP, DCT Solutions
At Medable, we’re always looking to understand the changing environment of clinical research, and how we can help customers overcome the various challenges, risks, and scenarios that these changes bring.
For the past year, I, various clinicians, and research experts at Medable have been working closely to improve how we conduct research for various therapeutic areas. Much like the results shown in Tufts CSDD’s latest whitepaper, we believe that a well-thought, decentralized approach can help bring new therapies in historically challenging therapeutic areas to markets faster.
The result of this work is a brand-new decentralized approach we’re bringing to the market.
Five myths about eConsent
As our industry continues to follow new paths to digitization, it’s important to debunk the most prevalent myths — both old and new — and reach a deeper understanding of decentralized clinical trials.
DCT takes center stage at DIA 2022 with new Tufts CSDD Study
DIA 2022 provided four days worth of content spanning over 13 talk tracks and hundreds of speakers with three major takeaways.
Using clear language and the latest technology in informed consent forms (ICFs) for clinical trials
Explore ways to improve the consenting communication process using clear language and the latest technology.
Clinician Reported Outcomes (CROs): A universal approach
Get the basics on ClinROs, why they are important, the industry governance around them, and how their electronic versions can benefit clinical trials.
Designing patient-friendly ePRO instruments
This blog explores why patient-centric ePRO instrument design is critical to driving study success, provides tips on how to make instruments more patient-centric, and offers resources for additional ePRO design guidance.
Improving diversity in clinical trials: An industry leader talks progress and surprises
We sat down with Rosamund Round, VP, Patient Innovation Center and Decentralized Trials at Parexel, about the challenge of improving diversity in clinical trials and what Parexel is doing to meet it.